A Agilent Technologies Inc.

Agilent Technologies Receives Multiple Awards at Scientific Conference in China

Agilent Technologies Inc. (NYSE: A) today, announced that it received three awards at the Annual Conference of China Scientific Instruments (ACCSI 2017) in Nanjing, China.

Agilent received the following awards: Green Product of the Year, Most Popular Scientific Instrument, and Most Influential Foreign Manufacturer.

This year’s ACCSI conference brought together leaders from diverse industries to discuss topics that ranged from bioscience to food safety and environmental monitoring. Agilent has attended ACCSI since 2008 and has received 28 awards to date.

The innovative Agilent Intuvo 9000 Gas Chromatograph (GC) System was selected as the Green Product of the Year. Designed together with customers, for customers, this transformational gas chromatograph makes complex technology easy to use. Click-and-run connections eliminate ferrules, guard-chip technology extends column life, and the trim-free column reduces retention time shifts due to column trimming maintenance.

“We are pleased to receive the Green Product of the Year Award from the 2017 ACCSI conference,” said Shanya Kane, Agilent global vice president and general manager of Gas Chromatography. “The basis for this award corroborates the customer feedback we are receiving from labs across the globe regarding Intuvo’s contributions to laboratory throughput, space, and power efficiencies, as well as the designed-in simplicity of the user interface and operation.”

The Agilent 5977B GC/MS System won the award for Most Popular Scientific Instrument. This single quadrupole GC/MS system features a high-efficiency ion source, which maximizes the number of ions that are created and transferred out of the source body and into the quadrupole analyzer, resulting in 10 times greater sensitivity and detection limits as low as 1.5 fg IDL.

Additionally, for the second year in a row, Agilent was recognized at ACCSI as the Most Influential Foreign Manufacturer.

“We have made significant investments to provide innovative new offerings to the China market. We are driven to further improve our customers’ experiences, so we are proud that our efforts are being recognized by external agencies,“ said Mike McMullen, Agilent president, and CEO.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.20 billion in fiscal 2016 and employs about 12,500 people worldwide. Information about Agilent is available at www.agilent.com.

EN
04/05/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch